{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-258565","form_type":"8-K","ticker":"VERU","cik":"0000863894","company_name":"VERU INC.","filed_at":"2025-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.398093+00:00","generated_at":"2026-05-17T01:30:06.728645+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Veru prices $25.2M public offering of common stock and warrants; net proceeds ~$23.4M for enobosarm study","bullets":["Offering includes 1.4M common shares + 7M pre-funded warrants and 8.4M Series A and 8.4M Series B warrants at $3.00/unit.","Gross proceeds expected ~$25.2M; net proceeds ~$23.4M after underwriting discounts and expenses.","Closing expected on or about October 31, 2025, subject to customary conditions.","Proceeds primarily to fund Phase 2b PLATEAU clinical study of enobosarm; also for working capital and general corporate purposes.","Series A warrants expire 5 years from issuance; Series B warrants expire 3 years or upon meeting specific clinical milestones and stock price triggers."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-258565","json":"https://secwatch.observer/filing/0001193125-25-258565.json","markdown":"https://secwatch.observer/filing/0001193125-25-258565.md","text":"https://secwatch.observer/filing/0001193125-25-258565.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/863894/000119312525258565/0001193125-25-258565-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/863894/000119312525258565/d59421d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:30:06.728645+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}